Corcept Therapeutics Inc (CORT)
24.52
-0.54
(-2.15%)
USD |
NASDAQ |
May 03, 16:00
24.98
+0.46
(+1.88%)
After-Hours: 20:00
Corcept Therapeutics Cash from Financing (Quarterly): 0.766M for Dec. 31, 2023
Cash from Financing (Quarterly) Chart
Historical Cash from Financing (Quarterly) Data
Date | Value |
---|---|
December 31, 2023 | 0.766M |
September 30, 2023 | -3.916M |
June 30, 2023 | -145.75M |
March 31, 2023 | 0.181M |
December 31, 2022 | -0.061M |
September 30, 2022 | -13.96M |
June 30, 2022 | -2.756M |
March 31, 2022 | -0.506M |
December 31, 2021 | -206.97M |
September 30, 2021 | -23.64M |
June 30, 2021 | -26.03M |
March 31, 2021 | -45.95M |
December 31, 2020 | -0.661M |
September 30, 2020 | 5.866M |
June 30, 2020 | 6.804M |
March 31, 2020 | 0.205M |
December 31, 2019 | -0.144M |
September 30, 2019 | 2.696M |
June 30, 2019 | -15.91M |
March 31, 2019 | -15.29M |
December 31, 2018 | -12.03M |
September 30, 2018 | -8.27M |
June 30, 2018 | 4.044M |
March 31, 2018 | 1.922M |
December 31, 2017 | 2.567M |
Date | Value |
---|---|
September 30, 2017 | -1.841M |
June 30, 2017 | -4.971M |
March 31, 2017 | -3.708M |
December 31, 2016 | -0.823M |
September 30, 2016 | -2.769M |
June 30, 2016 | -0.538M |
March 31, 2016 | -2.966M |
December 31, 2015 | -0.195M |
September 30, 2015 | -1.481M |
June 30, 2015 | -0.766M |
March 31, 2015 | 15.52M |
December 31, 2014 | -1.129M |
September 30, 2014 | -1.249M |
June 30, 2014 | -0.612M |
March 31, 2014 | -0.089M |
December 31, 2013 | -0.592M |
September 30, 2013 | -0.378M |
June 30, 2013 | 0.00 |
March 31, 2013 | 0.00 |
December 31, 2012 | 0.204M |
September 30, 2012 | 76.01M |
June 30, 2012 | 0.198M |
March 31, 2012 | 13.16M |
December 31, 2011 | 0.045M |
September 30, 2011 | 0.283M |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (Quarterly) Range, Past 5 Years
-206.97M
Minimum
Dec 2021
6.804M
Maximum
Jun 2020
-24.72M
Average
-0.661M
Median
Dec 2020
Cash from Financing (Quarterly) Benchmarks
Ultragenyx Pharmaceutical Inc | 330.61M |
Alnylam Pharmaceuticals Inc | 28.91M |
Catalyst Pharmaceuticals Inc | -0.665M |
United Therapeutics Corp | -1.068B |
XOMA Corp | 124.49M |
Cash from Financing (Quarterly) Related Metrics
Cash from Operations (Quarterly) | 5.887M |
Cash from Investing (Quarterly) | 17.10M |
Free Cash Flow | 126.90M |
Free Cash Flow Per Share (Quarterly) | 0.0531 |
Free Cash Flow to Equity (Quarterly) | 5.887M |
Free Cash Flow to Firm (Quarterly) | 5.887M |
Free Cash Flow Yield | 4.63% |